Welcome to the Clinical Care Solutions Oncology podcast channel. Our podcast shows give you quick access to important content when you need it - at home, at your desk, or on the go.
…
continue reading
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us ...
…
continue reading
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
…
continue reading
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and ...
22:42
In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective m…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
18:54
Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of b…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL
18:10
In this week's episode we'll discuss HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Next, we'll learn about how 4D intravital imaging in mice reveals the key role of platelets as a source of procoagulant membranes in hemostasis. Finally, we'll hear about modifications to a common i…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape
17:37
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba. If you enjoyed our podcast episode, please revie…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
11:50
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells. In this podcast, experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Te…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors
0:59
In this week's episode we’ll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors. Featu…
…
continue reading
Introduced by Associate Editor Dr. Thomas Ortel, this bonus episode discusses the Review Series on Factor XI, published in volume 143 issue 15 of Blood Journal. Dr. Ortel is joined by contributing authors Owen McCarty, PhD, Gili Kenet, MD, and David Gailani, MD. Review Series Articles: Introduction to a review series on factor XI Biology of factor …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
16:56
In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
18:41
This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually. You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Rad…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML
23:31
In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro an…
…
continue reading
In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD
16:59
In this week's episode we’ll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
11:58
Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity ...
22:53
In this week's episode we’ll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosph…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
16:00
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
21:50
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles: EVIDENCE meta-analysis: evaluating minimal …
…
continue reading
The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
23:32
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Featured Articles:…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Novel developments in lower-risk MDS & important practical considerations when treating patients
51:42
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of SOX11 expression to EBV-negative Burkitt lymphomas
19:58
In this week's episode we'll learn about the clinical benefit of complete remission with partial hematological recovery, or CRh, in patients with Acute Myeloid Leukemia (AML) treated with molecularly targeted drugs. Then we'll hear about a large cohort of patients with PNH were studied to detail PNH-related thrombotic events, unravel determinants o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
16:18
BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome
23:25
In this week's episode we’ll discuss the mutational and transcriptional landscape of pediatric BCP lymphoblastic leukemia; learn more about the role of platelet-derived TGF-β1 in immune thrombocytopenia; and discuss the findings from a phase 3 trial of mavorixafor in WHIM syndrome. Featured Articles: Mutational and transcriptional landscape of pedi…
…
continue reading
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is p…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
12:10
In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL
19:57
In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential …
…
continue reading
Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens with a review of how AML escapes T-cell–driven elimination and then focuses on how p53 function impinges on AML recognition by immune cells. The series finishes with a summary of new approaches t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
8:43
Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…
…
continue reading
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL. Our Guest: Dr. Stephen Opat is the direct…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease
23:39
In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
19:16
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell tran…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
46:31
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma ...
23:05
In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
34:39
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML
18:59
In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia
22:26
In this week's episode we’ll discuss the effects of voxelotor on cerebral blood flow in pediatric sickle cell disease, learn more about venous and arterial thrombosis in patients with Vexas syndrome, and discuss differential sensitivity to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia. Featured Articles: The influence of voxe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons
19:40
In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
12:34
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
27:24
The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and ...
21:44
In this week's episode we’ll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcrip…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
11:43
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins
19:10
In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researche…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
22:50
Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction ...
23:49
In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and …
…
continue reading
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies. Our Guest: Dr. Barbara Melosky Dr Melosky is a Professor of Medicine at the University of British Columbia and a Med…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
19:00
In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients wi…
…
continue reading
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. Our Guests: Dr. Christine Brezden-Masley Dr. Brezden-Masley is a …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Jak2V617F clonal hematopoiesis promotes arterial thrombosis; Staphylococcus aureus infection in Sézary syndrome; clinical features of RAC2-related immunodeficiency
26:18
In this week's episode we’ll discuss the mechanism by which Jak2V617F clonal hematopoiesis promotes arterial thrombosis, discuss how Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome, and learn more about the clinical and functional features of RAC2-related immunodeficiency. Featured Articles: Jak2V617F clonal hemat…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
43:51
In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Molecular mimicry in aplastic anemia; emicizumab prophylaxis in infants with hemophilia; hydroxyurea reduces infections in SCA
19:54
In this week's episode we'll discuss molecular mimicry in aplastic anemia, novel experiments show that antigens associated with viral infections can mimic epitopes presented on hematopoietic progenitor cells. Then, we'll learn about prophylaxis with subcutaneous emicizumab in infants with hemophilia. Finally we'll see how hydroxyurea is associated …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
22:22
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …
…
continue reading